Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion SCORE study report 15

JAMA Ophthalmology

Volumn 133, Issue 9, 2015, Pages 1022-1029

  Aref, Ahmad A ^a   Scott, Ingrid U ^b   Oden, Neal L ^c   Ip, Michael S ^d   Blodi, Barbara A ^d   Van Veldhuisen, Paul C ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINA VEIN OCCLUSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PHASE 3 CLINICAL TRIAL; RETINAL VEIN OCCLUSION; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETINAL VEIN OCCLUSION; RISK FACTORS; TIME FACTORS; TONOMETRY, OCULAR; TRIAMCINOLONE ACETONIDE;

EID: 84941313014     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.1823     Document Type: Article

References (32)

1. The Central Vein Occlusion Study. Baseline and early natural history report. Arch Ophthalmol. 1993; 111(8):1087-1095.
2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33(2):111-131.
3. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associatedwith macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
4. IpMS, Scott IU, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associatedwith macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5. Arch Ophthalmol. 2009;127(9):1101-1114.
5. Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin. 2007;23(6):1253-1258.
6. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006; 90(8):999-1003.
7. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116(3):455-460.
8. Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS. Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol. 2007;143(2):365-367.
9. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008; 28(4):573-580.
10. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740-743.
11. Chuang LH, Yeung L, Wang NK, Chen HS, KuWC, Lai CC. Secondary ocular hypertension after intravitreal injection with 2mg or 4mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(4):325-328.
12. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006;26(8):889-895.
13. Protocol for the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study [computer program]. Version 4. 0. Bethesda, MD: National Eye Institute; 2008. NTIS order No. PB2008-106870.
14. Manual of Policies and Procedures (MOPP) for the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study [computer program]. Version 4. 0. Bethesda, MD: National Eye Institute; 2008. NTIS order No. PB2008-106870.
15. Scott IU, VanVeldhuisen PC, Oden NL, et al; SCORE Study Investigator Group. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patientswith retinal vein occlusion. Ophthalmology. 2009;116(3):504-512.
16. Francis BA, Varma R, Chopra V, Lai MY, Shtir C, Azen SP; Los Angeles Latino Eye Study Group. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008; 146(5):741-746.
17. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol. 1991; 109(8):1090-1095.
18. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, HusseinM; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279.
19. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108 (11):1943-1953.
20. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressurereduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498-505.
21. Joe MK, Sohn S, Kim TE, Im JE, Choi YR, Kee C. Analysis of glucocorticoid-induced MYOC expression in human trabecular meshwork cells. Vision Res. 2011;51(9):1033-1038.
22. Wang YS, Friedrichs U, EichlerW, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002;240 (1):42-48.
23. Matsumoto Y, Johnson DH. Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ. Invest Ophthalmol Vis Sci. 1997;38(9):1902-1907.
24. Jonas J, Heatley G, Spaide R, Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma. 2005;14(2):168-171.
25. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163-167.
26. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand. 2005;83(6):645-663.
27. Shukla D, Vidhya N, Prasad NM, Mahalakshmi R, Kolluru C, Krishnadas R. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144(3):453-454.
28. Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol. 2005;33(3):252-258.
29. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14(2):73-85.
30. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121(1):57-61.
31. Ober MD, Barile GR, Tari SR, Tosi GM, Schiff WM, Chang S. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection [published correction appears in Am J Ophthalmol. 2007;143(4):736]. Am J Ophthalmol. 2006;142(4): 597-600.
32. Zacharias LC, Lin T, Migon R, et al. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina. 2013;33(3):522-531.